

# Psoriatic Arthritis and Cardiovascular Disease

Patients with PsA have a

# 43%

increased risk of CVD compared with the general population<sup>1</sup>




**Compared to the general population, patients with PsA have increased morbidity risks for....**



CVD is the leading cause of mortality in PsA accounting for **36-38%** of deaths.<sup>2</sup>

Based on early outpatient cohort studies from UK and Canada.<sup>2</sup>

PsA and cardiometabolic disease share common inflammatory pathways, with systemic inflammation driven by TNF- $\alpha$ , IL-17, and IL-6 promoting endothelial dysfunction, insulin resistance, and atherosclerotic plaque formation.<sup>3-5</sup>



Adipose tissue dysregulation further amplifies this risk. Qualitative and quantitative changes in adipokine signaling impair multiple organ systems, compounding cardiovascular vulnerability in PsA.<sup>5</sup>

## Guideline Recommendations

**EULAR recommends** that all patients with PsA should be screened for cardiovascular risk factors, with modifiable risk factors actively managed to improve CV outcomes.<sup>6</sup>

**GRAPPA recommends** addressing comorbidities, including obesity, metabolic syndrome, and CVD, as an integral part of PsA management, with multidisciplinary input where needed.<sup>7</sup>

CV=cardiovascular; CVD=cardiovascular disease; EULAR-European Alliance of Associations for Rheumatology; GRAPPA=Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; IL=interleukin; MI=myocardial infarction; PsA=psoriatic arthritis; TNF=tumor necrosis factor; UK=United Kingdom.

1. Polachek A, et al. *Arthritis Care Res*. 2017;69:67-74. doi:10.1002/acr.22926.2. Dey M, et al. *Ther Adv Musculoskelet Dis*. 2024;16: 1-12 doi:10.1177/1759720X241274537. 3. Porta S, et al. *Front Immunol*. 2021;11:590749. doi:10.3389/fimmu.2020.5907492. 4. Russolillo A, et al. *Clin Rheumatol*. 2013;52(1):62-67.5. Radic M, et al. *Metabolites*. 2025;15(3):206. doi:10.3390/metabo15030206.6. Gossec L, et al. *Ann Rheum Dis*. 2024;83:706-719.7. Coates LC, et al. *Nat Rev Rheumatol*. 2022;18(8):465-479.

MMAT-02961 © 2026 Eli Lilly and Company. All rights reserved.